Use of mechanical devices to reduce stroke in atrial fibrillation

Peter Pollak, David Holmes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Atrial fibrillation is common, and its incidence is increasing. The preponderance of strokes occurring in non-valvular atrial fibrillation is attributable to thromboembolism from clot formed within the left atrial appendage (LAA). Current standard of care involves long-term oral anticoagulation to decrease the risk of clot formation; however, this strategy is complicated by a narrow therapeutic window with a significant incidence of bleeding complications. Early evidence suggests that surgical obliteration of the left atrial appendage reduces stroke risk, and more recently several percutaneous approaches to left atrial appendage treatment have been developed aimed at eliminating the appendage cavity to reduce stroke risk through plugging or ligation. The most studied device, the Watchman device (Boston Scientific, Marlborough, MA), has been shown to be non-inferior to adjusted-dose warfarin in non-valvular atrial fibrillation at reducing the risk of stroke. Unanswered questions surround optimal patient selection criteria for device occlusion of the left atrial appendage and comparison with novel oral anticoagulants. Moreover, multiple devices are in development and early stages of evaluation. Device-based occlusion of the left atrial appendage is a promising alternative to long-term oral anticoagulation to reduce stroke risk in patients with non-valvular atrial fibrillation.This chapter describes the role of the left atrial appendage in cardioembolic stroke in patients with atrial fibrillation and the basis of appendage closure to reduce stroke risk. We review the procedurally relevant anatomy of the left atrial appendage and discuss the surgical and percutaneous approaches and devices used to close the left atrial appendage.

Original languageEnglish (US)
Title of host publicationPathophysiology and Pharmacotherapy of Cardiovascular Disease
PublisherSpringer International Publishing
Pages1081-1099
Number of pages19
ISBN (Electronic)9783319159614
ISBN (Print)9783319159607
DOIs
StatePublished - Jan 1 2015

Fingerprint

Atrial Appendage
Atrial Fibrillation
Stroke
Equipment and Supplies
Patient Selection
Thromboembolism
Incidence
Warfarin
Standard of Care
Anticoagulants
Ligation
Anatomy
Hemorrhage
Therapeutics

Keywords

  • Amplatz cardiac plug
  • Atrial fibrillation
  • AtriClip
  • Closure
  • Device
  • Left atrial appendage
  • PLAATO
  • Stroke
  • Watchman
  • WaveCrest

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pollak, P., & Holmes, D. (2015). Use of mechanical devices to reduce stroke in atrial fibrillation. In Pathophysiology and Pharmacotherapy of Cardiovascular Disease (pp. 1081-1099). Springer International Publishing. https://doi.org/10.1007/978-3-319-15961-4_51

Use of mechanical devices to reduce stroke in atrial fibrillation. / Pollak, Peter; Holmes, David.

Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Springer International Publishing, 2015. p. 1081-1099.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pollak, P & Holmes, D 2015, Use of mechanical devices to reduce stroke in atrial fibrillation. in Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Springer International Publishing, pp. 1081-1099. https://doi.org/10.1007/978-3-319-15961-4_51
Pollak P, Holmes D. Use of mechanical devices to reduce stroke in atrial fibrillation. In Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Springer International Publishing. 2015. p. 1081-1099 https://doi.org/10.1007/978-3-319-15961-4_51
Pollak, Peter ; Holmes, David. / Use of mechanical devices to reduce stroke in atrial fibrillation. Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Springer International Publishing, 2015. pp. 1081-1099
@inbook{7960767f2be440f9a2edc54a916660db,
title = "Use of mechanical devices to reduce stroke in atrial fibrillation",
abstract = "Atrial fibrillation is common, and its incidence is increasing. The preponderance of strokes occurring in non-valvular atrial fibrillation is attributable to thromboembolism from clot formed within the left atrial appendage (LAA). Current standard of care involves long-term oral anticoagulation to decrease the risk of clot formation; however, this strategy is complicated by a narrow therapeutic window with a significant incidence of bleeding complications. Early evidence suggests that surgical obliteration of the left atrial appendage reduces stroke risk, and more recently several percutaneous approaches to left atrial appendage treatment have been developed aimed at eliminating the appendage cavity to reduce stroke risk through plugging or ligation. The most studied device, the Watchman device (Boston Scientific, Marlborough, MA), has been shown to be non-inferior to adjusted-dose warfarin in non-valvular atrial fibrillation at reducing the risk of stroke. Unanswered questions surround optimal patient selection criteria for device occlusion of the left atrial appendage and comparison with novel oral anticoagulants. Moreover, multiple devices are in development and early stages of evaluation. Device-based occlusion of the left atrial appendage is a promising alternative to long-term oral anticoagulation to reduce stroke risk in patients with non-valvular atrial fibrillation.This chapter describes the role of the left atrial appendage in cardioembolic stroke in patients with atrial fibrillation and the basis of appendage closure to reduce stroke risk. We review the procedurally relevant anatomy of the left atrial appendage and discuss the surgical and percutaneous approaches and devices used to close the left atrial appendage.",
keywords = "Amplatz cardiac plug, Atrial fibrillation, AtriClip, Closure, Device, Left atrial appendage, PLAATO, Stroke, Watchman, WaveCrest",
author = "Peter Pollak and David Holmes",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-15961-4_51",
language = "English (US)",
isbn = "9783319159607",
pages = "1081--1099",
booktitle = "Pathophysiology and Pharmacotherapy of Cardiovascular Disease",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Use of mechanical devices to reduce stroke in atrial fibrillation

AU - Pollak, Peter

AU - Holmes, David

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Atrial fibrillation is common, and its incidence is increasing. The preponderance of strokes occurring in non-valvular atrial fibrillation is attributable to thromboembolism from clot formed within the left atrial appendage (LAA). Current standard of care involves long-term oral anticoagulation to decrease the risk of clot formation; however, this strategy is complicated by a narrow therapeutic window with a significant incidence of bleeding complications. Early evidence suggests that surgical obliteration of the left atrial appendage reduces stroke risk, and more recently several percutaneous approaches to left atrial appendage treatment have been developed aimed at eliminating the appendage cavity to reduce stroke risk through plugging or ligation. The most studied device, the Watchman device (Boston Scientific, Marlborough, MA), has been shown to be non-inferior to adjusted-dose warfarin in non-valvular atrial fibrillation at reducing the risk of stroke. Unanswered questions surround optimal patient selection criteria for device occlusion of the left atrial appendage and comparison with novel oral anticoagulants. Moreover, multiple devices are in development and early stages of evaluation. Device-based occlusion of the left atrial appendage is a promising alternative to long-term oral anticoagulation to reduce stroke risk in patients with non-valvular atrial fibrillation.This chapter describes the role of the left atrial appendage in cardioembolic stroke in patients with atrial fibrillation and the basis of appendage closure to reduce stroke risk. We review the procedurally relevant anatomy of the left atrial appendage and discuss the surgical and percutaneous approaches and devices used to close the left atrial appendage.

AB - Atrial fibrillation is common, and its incidence is increasing. The preponderance of strokes occurring in non-valvular atrial fibrillation is attributable to thromboembolism from clot formed within the left atrial appendage (LAA). Current standard of care involves long-term oral anticoagulation to decrease the risk of clot formation; however, this strategy is complicated by a narrow therapeutic window with a significant incidence of bleeding complications. Early evidence suggests that surgical obliteration of the left atrial appendage reduces stroke risk, and more recently several percutaneous approaches to left atrial appendage treatment have been developed aimed at eliminating the appendage cavity to reduce stroke risk through plugging or ligation. The most studied device, the Watchman device (Boston Scientific, Marlborough, MA), has been shown to be non-inferior to adjusted-dose warfarin in non-valvular atrial fibrillation at reducing the risk of stroke. Unanswered questions surround optimal patient selection criteria for device occlusion of the left atrial appendage and comparison with novel oral anticoagulants. Moreover, multiple devices are in development and early stages of evaluation. Device-based occlusion of the left atrial appendage is a promising alternative to long-term oral anticoagulation to reduce stroke risk in patients with non-valvular atrial fibrillation.This chapter describes the role of the left atrial appendage in cardioembolic stroke in patients with atrial fibrillation and the basis of appendage closure to reduce stroke risk. We review the procedurally relevant anatomy of the left atrial appendage and discuss the surgical and percutaneous approaches and devices used to close the left atrial appendage.

KW - Amplatz cardiac plug

KW - Atrial fibrillation

KW - AtriClip

KW - Closure

KW - Device

KW - Left atrial appendage

KW - PLAATO

KW - Stroke

KW - Watchman

KW - WaveCrest

UR - http://www.scopus.com/inward/record.url?scp=84944097599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944097599&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15961-4_51

DO - 10.1007/978-3-319-15961-4_51

M3 - Chapter

AN - SCOPUS:84944097599

SN - 9783319159607

SP - 1081

EP - 1099

BT - Pathophysiology and Pharmacotherapy of Cardiovascular Disease

PB - Springer International Publishing

ER -